|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
1999-3-16
|
|
pubmed:abstractText |
Both paclitaxel and cisplatin have moderate activity in patients with metastatic or recurrent cancer of the cervix, and the combination of these two agents has shown activity and possible synergism in a variety of solid tumors. We administered this combination to patients with metastatic or recurrent cervical cancer to evaluate its activity.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
0732-183X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
17
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
761-6
|
|
pubmed:dateRevised |
2006-4-24
|
|
pubmed:meshHeading |
pubmed-meshheading:10071264-Adult,
pubmed-meshheading:10071264-Aged,
pubmed-meshheading:10071264-Alopecia,
pubmed-meshheading:10071264-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:10071264-Cisplatin,
pubmed-meshheading:10071264-Female,
pubmed-meshheading:10071264-Granulocyte Colony-Stimulating Factor,
pubmed-meshheading:10071264-Hematologic Diseases,
pubmed-meshheading:10071264-Humans,
pubmed-meshheading:10071264-Middle Aged,
pubmed-meshheading:10071264-Nausea,
pubmed-meshheading:10071264-Neoplasm Metastasis,
pubmed-meshheading:10071264-Neoplasm Recurrence, Local,
pubmed-meshheading:10071264-Neoplasm Staging,
pubmed-meshheading:10071264-Nervous System Diseases,
pubmed-meshheading:10071264-Paclitaxel,
pubmed-meshheading:10071264-Survival Analysis,
pubmed-meshheading:10071264-Uterine Cervical Neoplasms
|
|
pubmed:year |
1999
|
|
pubmed:articleTitle |
Phase II trial of paclitaxel and cisplatin in metastatic and recurrent carcinoma of the uterine cervix.
|
|
pubmed:affiliation |
Department of Clinical Therapeutics, Alexandra Hospital, University of Athens School of Medicine, Greece.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Clinical Trial, Phase II
|
